TILVANCE-301, A PHASE 3 STUDY OF LIFILEUCEL TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY COMBINED WITH PEMBROLIZUMAB (PEMBRO) VS PEMBRO ALONE IN TREATMENT-NA VE UNRESECTABLE OR METASTATIC MELANOMA

Category Primary study
JournalJournal for immunotherapy of cancer
Year 2023
This article has no abstract
Epistemonikos ID: 0ac6e27194346a18dde0e3f89c64df9f8865896c
First added on: Feb 29, 2024